RxDoctor Payments Data

Jina Ford, NP

Nurse Practitioner · Cedartown, GANPI 1235520214

Payments from drug & device makers

$1,698in general payments, 2019–2025

Across 77 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$505
  • AbbVie$209
  • Boston Scientific$152
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$142
  • Pfizer$140
  • Lilly USA, LLC$135
  • plus $416 from 9 others

What the payments were for

  • Food & beverage$1,65397%
  • Education$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,698 in reported general payments places this provider in the 80th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$35,496
Medicare patients
120
Services billed
870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban33$29,398
JardianceEmpagliflozin18$28,274
MounjaroTirzepatide16$24,096
OzempicSemaglutide23$23,110
LinzessLinaclotide13$17,942
Spiriva RespimatTiotropium Bromide13$10,716
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,659
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$6,917
SymbicortBudesonide/Formoterol Fumarate18$4,266
Albuterol Sulfate HfaAlbuterol Sulfate100$3,707
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$1,885
Ventolin HfaAlbuterol Sulfate19$1,445
Gabapentin81$1,403
Ropinirole Hcl33$999
Tamsulosin Hcl57$969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$39$38,99031 claims
PfizerEliquis$140$29,39833 claims
Lilly USA, LLCMounjaro$135$24,09616 claims
Novo NordiskOzempic$505$23,11023 claims
AbbVieLinzess$209$17,94213 claims
GSKTrelegy Ellipta$53$9,65911 claims
AstraZenecaSymbicort$129$4,26618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Cedartown

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →